Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company developing treatments for diabetes and obesity, announced on September 22, 2026, that it has commenced an underwritten public offering of its common stock. The company also intends to offer pre-funded warrants to purchase shares of its common stock to certain investors.

The offering is subject to market conditions, and the company may grant the underwriter a 30-day option to purchase an additional 15 percent of the total shares and warrants offered. Biomea Fusion stated that all securities in the offering would be sold by the company itself.

Konik Capital Partners, LLC is acting as the sole underwriter for the proposed offering. The company has filed a shelf registration statement with the U.S. Securities and Exchange Commission (SEC) to facilitate the offering. Details regarding the terms and completion of the offering are uncertain and dependent on market conditions.

Biomea Fusion is focused on developing its oral small molecule therapies, icovamenib and BMF-650, for metabolic disorders, including diabetes and obesity. The company aims to provide transformative treatments for patients with these conditions, which affect a significant portion of the global population.